Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway.
A blood test identifies patients likely to fail combination HER2 therapy in colorectal cancer, helping doctors avoid ineffective treatments.
Baseline ctDNA profiling in HER2-amplified mCRC identifies anti-EGFR resistance alterations in over one-quarter of patients, predicting complete failure of dual HER2-targeted therapy (0% vs 31.3% response rate). Combining ctDNA resistance status with prior anti-EGFR therapy history provides a practical framework for selecting patients most likely to benefit from pertuzumab plus trastuzumab.
What the study was
- Study design
- Integrated analysis of two prospective trials (TRIUMPH + MyPathway)
- Population
- HER2-amplified metastatic colorectal cancer, tissue RAS wild-type
- Sample size
- 66
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- ESMO Open
Why it surfaced
Integrates ctDNA profiling with clinical history to practically guide dual HER2 therapy selection — 0% response if ctDNA resistance alteration present is a clinically actionable finding. Small n=66 limits generalizability. NOVEL_TREATMENT flag auto-elevates to HIGH.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.